Combination therapy for advanced colorectal cancer with RAS mutation
Part of Brain & nervous system, Cancer, Digestive system, Genetic & congenital clinical trials.
This trial tests whether a combination of targeted radiation (SBRT), chemotherapy (CAPEOX), a biologic drug (bevacizumab), and an immunotherapy (PD-1 inhibitor) can help people with a specific type of advanced colorectal cancer that cannot be removed by surgery. It is for patients whose tumors have a RAS gene mutation and are microsatellite stable (MSS).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your colorectal cancer has a RAS mutation and is microsatellite stable (MSS).
- Your cancer has spread and cannot be removed by surgery.
- You have not had any prior chemotherapy, immunotherapy, or other cancer treatment for this condition.
- Your overall health is good (able to perform daily activities without significant help).
- The tumor is located at least 12 cm (about 5 inches) from the anal opening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (pembrolizumab) plus targeted therapy (bevacizumab) and chemotherapy (CapeOX) given before surgery for a specific type of locally advanced colorectal cancer. It is designed for patients whose tumors have a RAS mutation, are BRAF normal, and are microsatellite stable.
This trial tests a new drug called XS-03 combined with standard chemotherapy and bevacizumab for people with metastatic colorectal cancer that has a specific genetic change called a RAS mutation. It aims to see if this combination is more effective than current treatments.
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
This trial is testing a combination of chemotherapy and targeted therapy with or without adding radiation and two immunotherapy drugs for advanced rectal cancer that has spread. It looks at whether adding radiation and immunotherapy can help control the cancer better for people with certain genetic types (RAS mutation and pMMR).
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
This trial tests a new combination therapy for advanced colorectal cancer that has not responded to standard treatments or is newly diagnosed. It aims to see if the combination can shrink tumors or slow their growth.
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.